[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618430":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":44,"studyPopulation":37,"armGroups":45,"interventions":63,"overallOfficials":75,"centralContacts":80,"locations":90,"responsibleParty":156,"collaborators":158,"id":161,"slug":37,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":162,"sex":168,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":37,"studyType":174,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":109,"whyStopped":37,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},{"fullName":5,"class":6},"Oulu University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":37},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of smoking cessation","The percentage of participants who have quitted smoking between the study arms 1 vs. 2","three months",[14,17,19,23,27,31,34],{"measure":10,"description":15,"timeFrame":16},"The percentage of participants who have quitted smoking between all the study arms","Three months",{"measure":10,"description":15,"timeFrame":18},"12 and 24 months",{"measure":20,"description":21,"timeFrame":22},"Rate of long-term smoking cessation","The percentage of participants who have had abstinence of smoking for at least six months","12 and 24 moths",{"measure":24,"description":25,"timeFrame":26},"LDCT findings","The percentage of LDCT negative, indetermined, and positive findings by screening round","baseline and 24 months",{"measure":28,"description":29,"timeFrame":30},"Sensitivity and specificity of LDCT screening examination","Sensitivity and specificity of LDCT screening examination for lung cancer detection (arms 1\\&2 vs. 3)","24 months, 36 months, and 10 years",{"measure":32,"description":33,"timeFrame":30},"Lung cancer incidence","Lung cancer incidence (stage specific) (arms 1\\&2 vs. 3)",{"measure":35,"description":35,"timeFrame":36},"Frequency of self-reported smoking cessation verified with CO measurement","24 months",null,{"allocation":39,"interventionModel":40,"interventionModelDescription":37,"primaryPurpose":41,"observationalModel":37,"timePerspective":37,"maskingInfo":42},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":43,"maskingDescription":37,"whoMasked":37},"NONE","The study population consists of individuals aged 50-74 years with a significant smoking history who continue to smoke. The study design is a prospective and participants are randomized into three study arms: low-dose CT (LDCT) + smoking cessation with a smartphone application (arm 1), LDCT + smoking cessation with written materials (arm 2), smoking cessation with a smartphone application without LDCT (arm 3). The study compares effectiveness of smoking cessation methods, LDCT in lung cancer screening, lung cancer stage distribution, and lung cancer specific survival.",[46,53,59],{"label":47,"type":48,"description":49,"interventionNames":50},"Arm 1","EXPERIMENTAL","Smoking cessation with a smartphone application + LDCT lung cancer screening",[51,52],"Other: Smartphone application","Other: low-dose computed tomography",{"label":54,"type":55,"description":56,"interventionNames":57},"Arm 2","ACTIVE_COMPARATOR","Smoking cessation with written materials + LDCT lung cancer screening",[52,58],"Other: Written materials for smoking cessation",{"label":60,"type":55,"description":61,"interventionNames":62},"Arm 3","Smoking cessation with a smartphone application without LDCT lung cancer screening",[51],[64,68,72],{"type":6,"name":65,"description":66,"armGroupLabels":67,"otherNames":37},"Smartphone application","Suunta smartphone application for smoking cessation",[47,60],{"type":6,"name":69,"description":70,"armGroupLabels":71,"otherNames":37},"low-dose computed tomography","Low-dose computed tomography based screening for lung cancer",[47,54],{"type":6,"name":73,"description":73,"armGroupLabels":74,"otherNames":37},"Written materials for smoking cessation",[54],[76],{"name":77,"affiliation":78,"role":79},"Tytti Särkeälä, PhD","Finnish Cancer Society","STUDY_DIRECTOR",[81,86],{"name":82,"role":83,"phone":84,"phoneExt":37,"email":85},"Jussi P Koivunen, MD, PhD","CONTACT","+358504182666","jussi.koivunen@pohde.fi",{"name":87,"role":83,"phone":88,"phoneExt":37,"email":89},"Sanna Iivanainen, MD, PhD","+358504178347","sanna.iivanainen@pohde.fi",[91,108,118,131,143],{"facility":92,"status":93,"city":94,"state":37,"zip":37,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":102,"contacts":103},"Helsinki University Hospital","NOT_YET_RECRUITING","Helsinki","Finland","FI",{"type":98,"coordinates":99},"Point",[100,101],24.93545,60.16952,{"lat":101,"lon":100},[104],{"name":105,"role":83,"phone":106,"phoneExt":37,"email":107},"Ilkka Ilonen, MD, PhD","+358504272280","ilkka.ilonen@hus.fi",{"facility":5,"status":109,"city":110,"state":37,"zip":37,"country":95,"countryCode":96,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"RECRUITING","Oulu",{"type":98,"coordinates":112},[113,114],25.46816,65.01236,{"lat":114,"lon":113},[117],{"name":82,"role":83,"phone":84,"phoneExt":37,"email":37},{"facility":119,"status":93,"city":120,"state":37,"zip":37,"country":95,"countryCode":96,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Tampere University Hospital","Tampere",{"type":98,"coordinates":122},[123,124],23.78712,61.49911,{"lat":124,"lon":123},[127],{"name":128,"role":83,"phone":129,"phoneExt":37,"email":130},"Hannele Hasala, MD, PhD","+358444735254","hannele.hasala@pirha.fi",{"facility":132,"status":93,"city":133,"state":37,"zip":37,"country":95,"countryCode":96,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Turku University Hospital","Turku",{"type":98,"coordinates":135},[136,137],22.26869,60.45148,{"lat":137,"lon":136},[140],{"name":141,"role":83,"phone":142,"phoneExt":37,"email":37},"Maria Silvoniemi, MD, PhD","+35823138709",{"facility":144,"status":93,"city":145,"state":37,"zip":37,"country":95,"countryCode":96,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Vaasa Central Hospital","Vaasa",{"type":98,"coordinates":147},[148,149],21.61577,63.096,{"lat":149,"lon":148},[152],{"name":153,"role":83,"phone":154,"phoneExt":37,"email":155},"Heidi Andersen, MD, PhD","+358401763563","heidi.andersen@ovph.fi",{"type":157,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[159],{"name":78,"class":160},"UNKNOWN","100618430",false,"NCT07331519","Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer","Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer - a Randomized Study","ISC-LDCT","Inclusion Criteria:\n\n1. Able to provide written informed consent\n2. Age between 50-74\n3. Smoked ≥ 15 cigarettes\u002Fday for ≥ 25 years or smoked ≥ 10 cigarettes\u002Fday for ≥ 30 years and are active smokers (smoking during the last two weeks)\n4. Access to a smartphone (iPhone or Android)\n\nExclusion Criteria:\n\n1. Current or past melanoma, lung, renal or breast cancer\n2. A chest CT examination less than one year before inclusion\n3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n4. No access to a smartphone (iPhone or Android)\n5. Participant is unwilling or unable to comply with treatment and trial instructions\n6. Any condition that study investigators consider an impediment to safe trial participation","ALL","50 Years","74 Years",{"count":172,"type":173},1200,"ESTIMATED","INTERVENTIONAL",[176],"NA","The study investigates effectiveness of different smoking cessation methods and low-dose CT based lung cancer screening",[179],"Smoking Cessation",[181,182,183,184],"smoking cessation","lung cancer","low-dose CT","lung cancer screening","2026-02-05",{"date":187,"type":188},"2026-02-06","ACTUAL",{"date":190,"type":188},"2026-02-02",{"date":192,"type":173},"2036-08-31",{"name":5,"class":6},5]